16 September 2026 editorial review · Item
Genprex GPX-002 (AAV Pdx1 + MafA alpha-to-beta reprogramming): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Genprex mouse papers support alpha-cell reprogramming but show recurrent autoimmunity after about four months in NOD mice. Primate work and company timelines remain development claims; no human T1D efficacy was located.
- Primary publication/regulatory sources checked or consulted: PMID 29304344; PMID 36879848.
- Programme/sponsor/conference source boundary: Diabetes Gene Therapy — GPX-002 (Genprex program page) (manufacturer); Genprex Provides Clinical Update on Diabetes Gene Therapy Program (manufacturer); Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting (manufacturer).